AIMS/HYPOTHESIS: We hypothesised that loss of peripheral fat in HIV patients would result in decreased plasma adipocytokines, in particular adiponectin, and that this decrease would be associated with changes in VLDL, IDL and LDL apolipoprotein B kinetics. METHODS: Plasma adiponectin, leptin and other cytokines were measured in uninfected control subjects (n=12) and three HIV-positive groups comprising treatment-naïve patients (n=15) and patients on triple antiretroviral therapy containing protease inhibitors (PI, n=15) or non-nucleoside reverse transcriptase inhibitors (NNRTI, n=25). VLDL, IDL and LDL apolipoprotein B kinetics were measured with an infusion of [1-(13)C] leucine. Regional body fat was measured with a dual energy X-ray absorptiometry scan. Insulin resistance was calculated using homeostasis model assessment (HOMA). RESULTS: Adiponectin (median [interquartile range]) was reduced in the treatment-naive (5.4 microg/ml [4.7-8.5]), PI (5.0 microg/ml [3.3-6.4]) and NNRTI (5.0 microg/ml [3.1-6.7]) groups compared with controls (9.7 microg/ml [6.9-13.3]) (p<0.05). In all subjects adiponectin correlated positively with HDL-cholesterol levels, the VLDL, IDL and LDL apolipoprotein B fractional clearance rates, and with the limb fat:lean body mass ratio (all p<0.01). Adiponectin correlated negatively with plasma triglyceride levels and HOMA (p<0.001). In a linear regression model that included HOMA, adiponectin was an independent predictor of VLDL and HDL-cholesterol levels and the IDL fractional clearance rate. TNF was higher in treatment-naive and PI subjects, and soluble TNF receptor superfamily, members 1A and 1B (previously known as TNF receptors 1 and 2) was higher in PI patients than in control subjects (p<0.05). CONCLUSIONS/ INTERPRETATION: Adiponectin levels are significantly reduced in treated and untreated HIV patients and are predictive of VLDL and IDL apolipoprotein B fractional clearance rates. Adiponectin may have a direct effect on lipoprotein metabolism, which may be independent of insulin.
AIMS/HYPOTHESIS: We hypothesised that loss of peripheral fat in HIV patients would result in decreased plasma adipocytokines, in particular adiponectin, and that this decrease would be associated with changes in VLDL, IDL and LDL apolipoprotein B kinetics. METHODS: Plasma adiponectin, leptin and other cytokines were measured in uninfected control subjects (n=12) and three HIV-positive groups comprising treatment-naïve patients (n=15) and patients on triple antiretroviral therapy containing protease inhibitors (PI, n=15) or non-nucleoside reverse transcriptase inhibitors (NNRTI, n=25). VLDL, IDL and LDL apolipoprotein B kinetics were measured with an infusion of [1-(13)C] leucine. Regional body fat was measured with a dual energy X-ray absorptiometry scan. Insulin resistance was calculated using homeostasis model assessment (HOMA). RESULTS: Adiponectin (median [interquartile range]) was reduced in the treatment-naive (5.4 microg/ml [4.7-8.5]), PI (5.0 microg/ml [3.3-6.4]) and NNRTI (5.0 microg/ml [3.1-6.7]) groups compared with controls (9.7 microg/ml [6.9-13.3]) (p<0.05). In all subjects adiponectin correlated positively with HDL-cholesterol levels, the VLDL, IDL and LDL apolipoprotein B fractional clearance rates, and with the limb fat:lean body mass ratio (all p<0.01). Adiponectin correlated negatively with plasma triglyceride levels and HOMA (p<0.001). In a linear regression model that included HOMA, adiponectin was an independent predictor of VLDL and HDL-cholesterol levels and the IDL fractional clearance rate. TNF was higher in treatment-naive and PI subjects, and soluble TNF receptor superfamily, members 1A and 1B (previously known as TNF receptors 1 and 2) was higher in PI patients than in control subjects (p<0.05). CONCLUSIONS/ INTERPRETATION: Adiponectin levels are significantly reduced in treated and untreated HIV patients and are predictive of VLDL and IDL apolipoprotein B fractional clearance rates. Adiponectin may have a direct effect on lipoprotein metabolism, which may be independent of insulin.
Authors: Jussi Sutinen; Anna-Maija Häkkinen; Jukka Westerbacka; Anneli Seppälä-Lindroos; Satu Vehkavaara; Juha Halavaara; Asko Järvinen; Matti Ristola; Hannele Yki-Järvinen Journal: AIDS Date: 2002-11-08 Impact factor: 4.177
Authors: M Schmitz; G M Michl; R Walli; J Bogner; A Bedynek; D Seidel; F D Goebel; T Demant Journal: J Acquir Immune Defic Syndr Date: 2001-03-01 Impact factor: 3.731
Authors: Katja Kannisto; Jussi Sutinen; Elena Korsheninnikova; Rachel M Fisher; Ewa Ehrenborg; Karl Gertow; Antti Virkamäki; Tuulikki Nyman; Hubert Vidal; Anders Hamsten; Hannele Yki-Järvinen Journal: AIDS Date: 2003-08-15 Impact factor: 4.177
Authors: Arnold Z Olali; Qiuhu Shi; Donald R Hoover; Mariana Bucovsky; Elizabeth Shane; Michael T Yin; Ryan D Ross Journal: Bone Date: 2021-09-20 Impact factor: 4.626
Authors: Vagner Raso; Roy J Shephard; Jorge Casseb; Alberto José da Silva Duarte; Paulo Roberto Santos Silva; Júlia Maria D'Andréa Greve Journal: Clinics (Sao Paulo) Date: 2013 Impact factor: 2.365
Authors: Eric M Ndombi; Valentine Budambula; Mark K Webale; Francis O Musumba; Jesca O Wesongah; Erick Mibei; Aabid A Ahmed; Raphael Lihana; Tom Were Journal: Endocr Connect Date: 2015-08-25 Impact factor: 3.335